Journal article
HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program
MP Kumarasinghe, A Morey, M Bilous, G Farshid, G Francis, G Lampe, G McCue, V Von Neumann-Cosel, SB Fox
Pathology | ELSEVIER SCIENCE BV | Published : 2017
Abstract
This Australian human epidermal growth factor receptor 2 (HER2) testing program aimed to analyse >800 cases tested in a coordinated setting to further evaluate the criteria to establish HER2 status in advanced gastric and gastro-oesophageal junction (GOJ) cancer. Heterogeneity, and minimum number of biopsy fragments for reliable HER2 assessment were also examined in a subset of samples. Five laboratories tested 891 samples referred to determine HER2 status for potential anti-HER2 treatment. Cancer site, specimen type (endoscopic biopsy/resection/metastases), immunohistochemistry (IHC) score, HER2 gene and CEP17 copy number (CN) and HER2:CEP17 ratios were recorded. Samples were derived from s..
View full abstractGrants
Funding Acknowledgements
Dr Belinda Butcher and Dr Sophie Gibb, WriteSource Medical Pty Ltd, provided statistical and medical writing services (respectively) funded by Roche Products Pty Limited.